Population
Patients undergoing first allogeneic sibling or unrelated donor transplant (URD) between 1990 and 2015 (n=102 557)
Intervention
Registry data study assessing incidence of acute GvHD (aGvHD)
Comparison
Patients were compared in the following time periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010, 2011-2015
Outcome
In multivariate analysis URD, not in CR at transplant or untreated, and female donor for male recipient were associated with increased risk whereas use of ATG/alemtuzumab decreased aGvHD incidence. Median follow-up was 214, 169, 127, 81 and 30 months for periods analyzed. 3-year-survival after aGvHD grades II-IV increased significantly from 38% to 40%, 43%, 44%, and 45%. In multivariate analysis URD, not in CR at transplant, peripheral blood as stem cell source, female donor for male recipient, and use of ATG/alemtuzumab were associated with increased mortality whereas reduced-intensity conditioning with lower one. Mortality increased with increasing patientsā age but decreased in the recent cohorts.